|3.12|| +0.12 / +4.00%|
Derma Sciences, Inc. is a medical technology company, focused on wound care. The company operates its business through three segments: Pharmaceutical Wound Care, Advanced Wound Care and Traditional Wound Care. The Pharmaceutical Wound segment offers DSC127, a novel product for the treatment of diabetic foot ulcers. The Advanced Wound Care segment includes MEDIHONEY, BIOGUARD, AMNIOEXCEL, AMNIOMATRIX, DERMAGRAN, ALGICELL AG, XTRASORB and TCC-EZ. The Traditional Wound Care segment consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It manufactures and markets adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. The company also offers skin care products, which includes barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils and moisturizers to nursing homes, hospitals, home healthcare agencies and other institutions. Derma Sciences was founded on September 10, 1984 and is headquartered in Princeton, NJ.
|Stephen T. Wills||Executive Chairman & Chief Executive Officer|
|Frederic Eigner||Executive Vice President-Operations|
|John E. Yetter||Chief Financial Officer & Senior VP-Finance|
|Barry J. Wolfenson||Group President-Advanced Wound Care|
|Edward Eisenlord||Vice President-Corporate Accounts|